<DOC>
	<DOCNO>NCT01198379</DOCNO>
	<brief_summary>The study prospectively initiate : ( 1 ) evaluate alteration platelet function aspirin therapy prevalence aspirin resistance patient chronic kidney disease undergoing hemodialysis , ( 2 ) compare incidence vascular event ( myocardial infarction , cardiac death , stroke , vascular access thrombosis , revascularization procedure ) safety profile among placebo-treated , aspirin-resistant aspirin-sensitive patient .</brief_summary>
	<brief_title>Aspirin Prevention Cardiovascular Events Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>patient endstage renal disease undergoing longterm hemodialysis . Patients exclude evidence recent history acute uremia , previous adverse reaction aspirin history aspirin hypersensitivity ( eg , aspirininduced asthma angioedema ) , concurrent treatment antiplatelet agent ( clopidogrel ticlopidine ) , steroidal drug , nonsteroidal antiinflammatory drug , high immediate risk bleeding ( eg , active peptic ulceration , recent injury , hemophilia ) , lifethreatening condition endstage renal disease vascular disease ( eg , nonskin cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>aspirin</keyword>
	<keyword>aspirin resistance</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>Prevalence aspirin resistance , cardiovascular event , safety profile</keyword>
</DOC>